Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes
These information might help the physician in the selection of a more suitable drug based on the needs/complications beyond glucose control
Nocturnal hypoglycaemia can trigger a counter-regulatory response involving adrenaline release, which may manifest as sweating, palpitations, and tremor during sleep
The quest continues
I would not be surprised if SUD eventually became a clinical indication for using a GLP-1. Lacking that, DeRoo said that the ideal patients who can benefit from GLP-1 off-label uses across mental health are those who already meet clinical criteria to receive a prescription for a GLP-1
Bruising at the injection site affects up to 30% of people starting GLP-1 medications like semaglutide, though it typically resolves within days